Abstract. Purine nucleosides, which accumulate in adenosine deaminase and purine nucleoside phosphorylase deficiency, are toxic to lymphoid cells. Since adenine nucleosides inhibit S-adenosylhomocysteine hydrolase, they could potentially decrease intracellular methionine synthesis. To test this hypothesis, we measured methionine synthesis by the use of ['4C]formate as a radioactive precursor in cultured human T and B lymphoblasts treated with varying concentrations of purine nucleosides; 2'-deoxycoformycin and 8-aminoguanosine were added to inhibit adenosine deaminase and purine nucleoside phosphorylase, respectively. In the T lymphoblasts methionine synthesis was inhibited -50% by 10 MAM of 2'-deoxyadenosine, adenine arabinoside, or 2'-deoxyguanosine. By contrast, in the B lymphoblasts methionine synthesis was considerably less affected by these nucleosides, with 50% inhibition occurring at 100 ,uM of 2'-deoxyadenosine and adenine arabinoside; 100 uM of2'-deoxyguanosine yielded <10% inhibition. Adenosine and guanosine were considerably less potent inhibitors of methionine synthesis in both the T and B lymphoblasts. An adenosine deaminasedeficient and a purine nucleoside phosphorylase-deficient cell line, both of B cell origin, exhibited sensitivities to the nucleosides similar to those of the normal B cell lines. In both the T and B cell lines homocysteine reversed the methionine synthesis inhibition induced by the adenine nucleosides and guanosine and largely reversed that induced by 2'-deoxyguanosine. Methionine synthesis from homocysteine generates free tetrahydrofolate from 5-methyltetrahydrofolate, the main intracellular storage form of folate. We conclude that punne nucleoside toxicity may be partly mediated through (a) decreased intracellular methionine synthesis, and (b) altered folate metabolism.
Introduction
A deficiency of either of two consecutive enzymes of the purine catabolic pathway, adenosine deaminase (E.C. 3.5.4.4.) or purine nucleoside phosphorylase (E.C. 2.4.2.1.) leads to altered immune system function (1, 2) . A deficiency of the former enzyme leads to severe combined immunodeficiency disease, a disorder of both T and B cell function with T cell function more profoundly affected, whereas deficiency of the latter enzyme leads to isolated T cell dysfunction. Although much is known about the biochemical consequences of these two enzyme deficiencies, the biochemical basis of purine nucleoside toxicity to lymphoid cells remains disputed.
Adenosine deaminase deficiency leads to the accumulation of adenosine (Ado)' and 2'-deoxyadenosine (dAdo), whereas purine nucleoside phosphorylase deficiency leads to the accumulation of inosine (Ino), 2'-deoxyinosine (dIno), guanosine (Guo), and 2'-deoxyguanosine (dGuo) (3, 4) . In most cell systems Ino and dIno are nontoxic, whereas Ado, dAdo, Guo, and dGuo are potent inhibitors of T and B cell proliferation. Some of the dAdo toxicity relates to the accumulation of dATP, a potent inhibitor of ribonucleotide diphosphate reductase, thus interfering with the synthesis of the other deoxynucleotides required for DNA synthesis (3) . This, however, cannot explain all of dAdo's toxicity since pyrimidine deoxynucleosides only partially reverse the toxicity, and, perhaps more important, resting non-DNA-synthesizing lymphocytes are lysed by dAdo (3, 5, 6) . Another major mechanism of dAdo toxicity is through inhibition of S-adenosylhomocysteine hydrolase (E.C. 3.3.1.1.), a property that is shared by the dAdo analogue adenine arabinoside (Ara-A) (7, 8) . Inhibition of this enzyme causes accumulation of S-adenosylhomocysteine and, as shown in Fig. 1 , this compound inhibits its own formation from S-adenosylmethionine, thus inhibiting most intracellular transmethylation reactions (9) . Inhibition of S-adenosylhomocysteine hydrolase should also reduce intracellular homocysteine production, and thus methionine synthesis, since the pathway depicted in Fig. 1 is the only mechanism mammalian cells have for generating homocysteine (10) .
We therefore measured methionine synthesis in normal T and B lymphoblasts and in B lymphoblasts deficient in adenosine deaminase or purine nucleoside phosphorylase treated with varying concentrations of several purine nucleosides. We used ['4C]formate as our radioactive precursor as previously described (11). We found that dAdo and Ara-A were potent inhibitors of methionine synthesis in T lymphoblasts and less potent inhibitors in B lymphoblasts, whereas Guo and dGuo inhibited methionine synthesis only in T lymphoblasts. Homocysteine fully reversed the inhibition induced by dAdo, Ara-A, and Guo but only partially reversed that induced by dGuo.
Methods
Origin of cell lines and cell culture. The two T lymphoblast lines, CCRF-CEM and MOLT4, were derived from acute T cell leukemias and were provided by Drs. Alice Yu and J. Edwin Seegmiller, respectively, both of the University of California, San Diego. Three of the four B lymphoblast lines, MGL8B2 (a normal cell line, from the Genetics Unit of the Massachusetts General Hospital, Boston, MA), 889 (an adenosine deaminase-deficient cell line, from Dr. Seegmiller's laboratory), and 679 (a purine nucleoside phosphorylase-deficient cell line, from Dr. Randall Willis of the University of California, San Diego) were established by Epstein-Barr virus transformation of pe- Figure 1 . Methionine synthesis and conversion to homocysteine. Reactions: (1) methionine synthetase; (2) methionine adenosyltransferase; (3) methyltransferase reactions; and (4) S-adenosylhomocysteine hydrolase. Hcy, homocysteine; Met, methionine; AdoMet, 5- adenosylmethionine; AdoHcy, S-adenosylhomocysteine; 5MTHF, 5-methyltetrahydrofolate; THF, tetrahydrofolate; and B12, cobalamin. The broken arrow indicates that S-adenosylhomocysteine inhibits its own formation from S-adenosylmethionine, thereby inhibiting most intracellular methylation reactions. ripheral blood lymphocytes, whereas the fourth, WIL-2, is a normal splenic-derived line. The two deficient cell lines had <1% of their respective enzyme activities. Cells were routinely grown in RPMI-1640 medium (Gibco Laboratories, Gibco Div., Grand Island, NY) supplemented with 10% fetal bovine serum and 2 mM glutamine in a humified atmosphere of 5% C02; they were regularly tested for mycoplasma by a biochemical assay.
Methionine biosynthesis assay. Cells were recovered by centrifugation from the RPMI growth medium and resuspended at a density of 1.5 X 106/ml in methionine-free modified Eagle's medium (Gibco Laboratories, Gibco Div.) (12) which was supplemented with 10 gM methionine, 100 MM folic acid, 1 MuM cobalamin, 10 jsg/ml 2-mercaptoethanol, 25 ug/ml human transferrin (one-third iron saturated), and 2 mg/ml bovine serum albumin-fatty acid mixture prepared as previously described (13) . At a methionine concentration of 10 RI) in the guanine nucleoside experiments. The former compound is a potent inhibitor of adenosine deaminase, and the latter compound inhibits purine nucleoside phosphorylase; these two nucleosides are not known to be S-adenosylhomocysteine hydrolase inhibitors (14) , and at these concentrations they did not affect rates of methionine synthesis. Neither 889, the adenosine deaminase-deficient cell line, nor 679, the purine nucleoside phosphorylase-deficient cell line, was pretreated with these inhibitors. The nucleoside to be tested was added and 30 min later rates of methionine synthesis were measured as previously described (I 1 
Results
Effects ofAdo, dAdo, or Ara-A on methionine synthesis. Ado, dAdo, and Ara-A inhibited methionine synthesis in the T and B lymphoblasts (Fig. 2) . Since similar patterns of sensitivity to these three adenine nucleosides were found in the two T lymphoblast lines, CCRF-CEM and MOLT4, and in the two B lymphoblast lines, MGL8B2 and WIL-2, only the data on CCRF-CEM (Fig. 2 A) and MGL8B2 ( Fig. 2 B) are shown. The adenosine deaminase-deficient lymphoblast line 889, a B cell line, exhibited a pattern of sensitivity (Fig. 2 C) similar to that observed in the two normal B lymphoblast lines. All three adenine nucleosides inhibited methionine synthesis more potently in the T lymphoblasts than in the B lymphoblasts. At a concentration of 0.1 ,uM, dAdo and Ara-A inhibited methionine synthesis by -20% in the T lymphoblasts, whereas similar inhibition in the B lymphoblasts required 3 ;iM of Ara-A and 10 gM of dAdo. Moreover, the concentrations at which methionine synthesis was decreased by 50% of the control value (i.e., the ID5e) were remarkably different between the two cell types. Thus, the ID5o was <10 IMM for either dAdo or Ara-A in the T lymphoblasts, and it was >100 MM for these nucleosides in the B lymphoblasts. Ado, compared with dAdo and Ara-A, was a less effective inhibitor of methionine synthesis, and only at concentrations >10 IM in the T lymphoblasts and 30 gM in the B lymphoblasts did it significantly inhibit methionine synthesis. At lymphoblasts. Thus, the absolute inhibition of methionine synthesis at these two concentrations of these nucleosides is even greater than that shown in Fig. 2 Effects ofGuo, dGuo, Ino, and dlno on methionine synthesis.
Both Guo and dGuo inhibited methionine synthesis (Fig. 3 indicate that increased cellular availability of purine bases does not affect the one-carbon pool which is labeled with ['4Clformate.
Reversal ofAdo, dAdo, and Ara-A inhibition ofmethionine synthesis by homocysteine. In the absence of purine nucleosides, 200 AM D,L-homocysteine thiolactone increased methionine synthesis in CCRF-CEM by 40% and in MGL8B2 by 44%, from -11 to 16 and from -9 to 13 pmol methionine/pmol leucine incorporated into protein, respectively (Table I) . This modest increase in methionine synthesis suggests that at 10 MM methionine, the concentration used in these experiments, the cell's generation of homocysteine may be submaximal. Thus, when exogeneous homocysteine is provided a small boost in methionine synthesis occurs.
When homocysteine thiolactone was added to either T or B cells treated with all concentrations of Ado, dAdo, or Ara-A, the nucleoside-induced inhibition of methionine synthesis was fully reversed (only the two highest concentrations of the nucleosides, 10 and 100 AM, are shown in Table I ). In the presence of homocysteine, Ado at concentrations <10 uM, and dAdo and Ara-A at all concentrations actually increased the incorporation of newly synthesized methionine into protein. Thus, at 100 MM of either dAdo or Ara-A the picomoles of methionine incorporated into protein per picomole of leucine incorporated increased significantly (P < 0.05, t test), from -16 to 21 and from -13 to 17 in CCRF-CEM and MGL8B2, respectively (Table I ). Ado at concentrations of >10 MM did not increase methionine incorporation into protein.
Reversal ofGuo and dGuo inhibition ofmethionine synthesis by homocysteine. The Guo-induced inhibition of methionine synthesis in CCRF-CEM was fully reversed by the addition of 1265 Methionine Synthesis in Nucleoside-treated Lymphoblasts Rates of methionine synthesis were measured as in the legend to Fig. 2 . D,L-homocysteine thiolactone (Hcy) was present at a concentration of 200 uM. The data are expressed as picomoles of methionine per picomole of leucine incorporated into protein and are the mean±SD of at least three independent experiments.
homocysteine thiolactone (Table II) . Again, as for dAdo and Ara-A, in the presence of homocysteine, Guo at all concentrations caused a small but statistically significant (P < 0.05, t test) increase in newly synthesized methionine incorporated into protein over that without the nucleoside. The dGuoinduced inhibition of methionine synthesis, on the other hand, was fully reversed only at nucleoside concentrations of .1 zM. At dGuo concentrations of >10 ,M only partial reversal occurred; at these relatively high dGuo concentrations protein synthesis was significantly inhibited and thus some of this reversal is fictitious. Nonetheless, even at these high dGuo concentrations, homocysteine induced at least a twofold increase in methionine synthesis when expressed as picomoles synthesized per milligram of cell protein.
Discussion
These studies demonstrate that adenine and guanine nucleosides and deoxynucleosides inhibit methionine synthesis in cultured T and B lymphoblasts. The deoxynucleosides were more potent inhibitors of methionine synthesis than were the cor- Rates of methionine synthesis were measured as in the legend to responding nucleosides, and T lymphoblasts were more sensitive to this methionine synthesis inhibition than were B lymphoblasts. These data, therefore, correlate with the results of growth studies that show that deoxynucleosides are more toxic to cultured lymphoblasts than are nucleosides and that T lymphoblasts are more sensitive to this toxicity than are B lymphoblasts (16) (17) (18) . Moreover, since the adenine nucleosides inhibited methionine synthesis in both the T and B lymphoblasts and the guanine nucleosides inhibited methionine synthesis only in the T lymphoblasts, the data may provide a biochemical basis to explain the clinical differences between adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. The mechanism of the observed decrease in methionine synthesis induced by the adenine nucleosides is presumably through their inhibition of S-adenosylhomocysteine hydrolase, which causes a decrease in intracellular homocysteine production (Fig. 1) . The data support this hypothesis because (a) Ara-A is a more potent inhibitor of S-adenosylhomocysteine hydrolase than is dAdo (7) and in the studies reported here was a more potent inhibitor of methionine synthesis, and (b) homocysteine fully reversed the adenine nucleoside-induced inhibition of methionine synthesis. Guo and dGuo do not inhibit purified human placental S-adenosylhomocysteine hydrolase (19) , nor do they inhibit the enzyme in erythrocyte lysates (20) . Our data, however, suggest that these guanine nucleosides do inhibit the enzyme in intact lymphoblasts, because homocysteine fully reversed the Guo-induced inhibition of methionine synthesis and partly reversed the dGuo-induced inhibition. It appears that dGuo may have an additional mechanism in inhibiting methionine synthesis.
By inhibiting S-adenosylhomocysteine hydrolase the nucleosides interrupt the cycle depicted in Fig. 1 The normal plasma methionine concentration ranges from 6 to 30 uM (22) (23) (24) . Since the purine nucleosides decreased methionine synthesis equally at 30 and 10 gM of methionine in the media, decreased methionine synthesis may occur clinically when S-adenosylhomocysteine hydrolase is inhibited. Thus, decreased intracellular methionine synthesis would be expected in children with either adenosine deaminase deficiency or purine nucleoside phosphorylase deficiency and in patients treated with Ara-A since in all three clinical settings Sadenosylhomocysteine activity is markedly reduced (19, 20, 25, 26) . Cautious administration of methionine might prove beneficial in these disorders.
Besides the potential starvation of the cell for methionine, the purine nucleoside-induced inhibition of methionine synthesis demonstrated in these studies could have another major detrimental effect. The methionine synthetase reaction is the only way the cell can regenerate free tetrahydrofolate from 5-methyltetrahydrofolate (27) (Fig. 1) . 5-Methyltetrahydrofolate is the main intracellular storage form of folates, normally accounting for -80% of all cellular folates (28) ; moreover, its formation from 5,10-methylenetetrahydrofolate is essentially irreversible in vivo (27) . Thus, inhibition of methionine synthesis could lead to trapping of folates as 5-methyltetrahydrofolate, much as occurs in cobalamin deficiency. In this regard it is interesting that at least one adenosine deaminase-deficient child and apparently all of the purine nucleoside phosphorylasedeficient children had megaloblastic anemia (2, 29, 30) . If folate trapping is shown to occur in purine nucleoside-treated cells, then folinic acid, much as it is used to limit methotrexate toxicity, might also be useful in these immunodeficiency states.
